|Articles|December 25, 2019

New Insights into Cold-Flu Relationship May Help Better Predict Outbreaks: Public Health Watch

Study finds coinfection is unlikely as Europe braces for influenza A.

We’ve all heard the old axiom, “Feed a cold. Starve a fever.”

Now, a new analysis suggests we may need to rethink our view of these 2 age-old maladies with much in common.

In findings, published on December 16th in the Proceedings of the National Academy of Sciences, investigators from the University of Glasgow in Scotland noted that people suffering from the common cold are less likely to be diagnosed with influenza virus, and vice versa. They believe this knowledge may help public health specialists better predict outcomes of the latter, which of course have been linked with significant disease burden and mortality.

“Our findings suggest that we need to do more coinfection studies in future research that involve respiratory viruses, including influenza,” coauthor Pablo Murcia, DVM, PhD, MSc, senior lecturer, University of Glasgow Centre for Virus Research, Institute of Infection, Immunity and Inflammation, told Contagion®. “Virologists have traditionally studied viruses in isolation—you study influenza or coronaviruses, for example. What our study shows is that viruses interact and in order to understand the mechanisms that explain the observed interactions we need to do more research. I think that increased awareness of the impact of virus-virus interactions in virus epidemiology and disease outcome would be beneficial, especially for infectious disease and public health specialists.”

For their research, Murcia and his team tested for 11 types of respiratory viruses in more than 44,000 samples taken from more than 36,000 people with acute respiratory illnesses. Of these samples, 35% tested positive for a virus, and 8% of those were infected with more than 1 virus.

Notably, according to Murcia, the most significant interaction was between influenza A viruses and rhinoviruses, aka the common cold. Computer modeling of these 2 viruses found that interactions between them inhibited infection with both. Overall, people with influenza A were about 70% less likely to also be infected with rhinovirus than those infected with other viruses.

The findings are particularly notable, given the threat posed by influenza A in Europe and elsewhere. According to new data from the European Centre for Disease Prevention and Control and the World Health Organization, initial virus detections for the 2019-20 season indicate cocirculation of influenza types A (71%) and B (29%) in the region. To date at least, the opposite has been the case here in the United States.

Unfortunately, as European epidemiologists note, increased circulation of influenza A could result in high mortality in elderly populations and a heavy burden on healthcare services.

“Epidemiological interactions between respiratory viruses have been postulated before,” Murcia said. “However, our study is the first one to provide strong statistical evidence on this issue. We were able to do that first because we had access to the diagnostic test results of tens of thousands of patients spanning multiple years and from a well-defined population here in Glasgow. A key aspect is that each patient that was tested, was screened for 11 different viruses in the same diagnostic lab. This very fact gave us a good picture of the virus status of each patient and also significant confidence about the reliability of our data.”

And it just may give epidemiologists a reliable way to predict influenza outbreaks in the future.


Related to this article

REMAP-CAP and the Tamiflu “Pre-Release”: A Set-Up for Disaster
Preliminary REMAP-CAP data suggesting oseltamivir may increase mortality in critically ill ICU influenza patients has sparked polarized reactions, but clinicians should await the full peer-reviewed manuscript before drawing broad conclusions, since the signal comes from a narrow, severely ill population and may reflect a therapeutic window effect rather than a blanket lack of efficacy.
GSK's mRNA Influenza Vaccine Moves to Phase 3 Trial
GSK will advance its investigational mRNA seasonal flu vaccine candidate, which targets both hemagglutinin and neuraminidase, into a phase 3 trial in September 2026 after the shot outperformed licensed flu vaccines in a phase 2 study.
How The Food Safety Surveillance Infrastructure Works in the US
In the first episode of our news series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates, and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
Ebola and the Ongoing Tale of US Failures
In mid-May, as the world was still grappling with an unexpected hantavirus outbreak aboard a tourism vessel, news broke of an Ebola outbreak in the Ituri Province of the Democratic Republic of the Congo spanning at least 3 health zones, including Bunia, Rwampara, and Mongbwalu.
This Week's Top 5 Infectious Disease News Stories: September 12-September 18, 2026
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
Measles Update: September 18, 2026
The latest CDC numbers show a 5.37% increase of measles cases from week-to-week. In Pennsylvania, the fourth measles-related death was reported in 2026. Additionally, the CDC has made a change in the way it will report deaths.